716 related articles for article (PubMed ID: 34536028)
1. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
Keskin AU; Bolukcu S; Ciragil P; Topkaya AE
J Med Virol; 2022 Jan; 94(1):39-41. PubMed ID: 34536028
[No Abstract] [Full Text] [Related]
2. Should a third booster dose be scheduled after two doses of CoronaVac? A single-center experience.
Yigit M; Ozkaya-Parlakay A; Cosgun Y; Ince YE; Bulut YE; Senel E
J Med Virol; 2022 Jan; 94(1):287-290. PubMed ID: 34487373
[TBL] [Abstract][Full Text] [Related]
3. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
4. Response and Duration of Serum Anti-SARS-CoV-2 Antibodies After Inactivated Vaccination Within 160 Days.
Xu QY; Xue JH; Xiao Y; Jia ZJ; Wu MJ; Liu YY; Li WL; Liang XM; Yang TC
Front Immunol; 2021; 12():786554. PubMed ID: 35003104
[TBL] [Abstract][Full Text] [Related]
5. A third booster dose may be necessary to mitigate neutralizing antibody fading after inoculation with two doses of an inactivated SARS-CoV-2 vaccine.
Yue L; Xie T; Yang T; Zhou J; Chen H; Zhu H; Li H; Xiang H; Wang J; Yang H; Zhao H; Wei X; Zhang Y; Xie Z
J Med Virol; 2022 Jan; 94(1):35-38. PubMed ID: 34516026
[No Abstract] [Full Text] [Related]
6. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
Ebinger JE; Fert-Bober J; Printsev I; Wu M; Sun N; Prostko JC; Frias EC; Stewart JL; Van Eyk JE; Braun JG; Cheng S; Sobhani K
Nat Med; 2021 Jun; 27(6):981-984. PubMed ID: 33795870
[TBL] [Abstract][Full Text] [Related]
7. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
8. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS
Front Immunol; 2021; 12():744887. PubMed ID: 34712232
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
[TBL] [Abstract][Full Text] [Related]
10. Humoral and cellular response to SARS-CoV-2 BNT162b2 mRNA vaccine in hemodialysis patients.
Melin J; Svensson MK; Albinsson B; Winqvist O; Pauksens K
BMC Immunol; 2021 Oct; 22(1):70. PubMed ID: 34666683
[TBL] [Abstract][Full Text] [Related]
11. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
12. Dual-Antigen COVID-19 Vaccine Subcutaneous Prime Delivery With Oral Boosts Protects NHP Against SARS-CoV-2 Challenge.
Gabitzsch E; Safrit JT; Verma M; Rice A; Sieling P; Zakin L; Shin A; Morimoto B; Adisetiyo H; Wong R; Bezawada A; Dinkins K; Balint J; Peykov V; Garban H; Liu P; Bacon A; Bone P; Drew J; Sanford DC; Spilman P; Sender L; Rabizadeh S; Niazi K; Soon-Shiong P
Front Immunol; 2021; 12():729837. PubMed ID: 34603305
[TBL] [Abstract][Full Text] [Related]
13. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
Front Immunol; 2022; 13():827306. PubMed ID: 35173736
[TBL] [Abstract][Full Text] [Related]
14. Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays.
Cuykx M; Mortelé O; Jansens H; Schouwers S; Meskal A; Hoffbauer I; Peeters B
Diagn Microbiol Infect Dis; 2021 Oct; 101(2):115486. PubMed ID: 34332306
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049
[TBL] [Abstract][Full Text] [Related]
16. Latest Russian vaccine comes with a big dose of mystery.
Dobrovidova O
Science; 2021 Apr; 372(6538):116-117. PubMed ID: 33833104
[No Abstract] [Full Text] [Related]
17. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
[TBL] [Abstract][Full Text] [Related]
18. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
19. A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge.
He X; Ding L; Cao K; Peng H; Gu C; Li Y; Li D; Dong L; Hong X; Wang X; Fu M; Qiu C; Zhu C; Zhang Z; Song S; Wang C; Jiang Z; Xie Y; Qi Z; Zhao C; Zhao P; Zhang X; Xu J
Emerg Microbes Infect; 2021 Dec; 10(1):1555-1573. PubMed ID: 34304724
[TBL] [Abstract][Full Text] [Related]
20. Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine.
Zhang J; He Q; An C; Mao Q; Gao F; Bian L; Wu X; Wang Q; Liu P; Song L; Huo Y; Liu S; Yan X; Yang J; Cui B; Li C; Wang J; Liang Z; Xu M
Emerg Microbes Infect; 2021 Dec; 10(1):1598-1608. PubMed ID: 34278956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
